Nonsmall Cell Lung Cancer, Solid Tumor, Adult
Conditions
Keywords
Lung Cancer; Solid Tumor, Immunotherapy, TCR-T Cell Therapy
Brief summary
Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.
Detailed description
1. Choose appropriate patients with KK-LC-1 expression in advanced lung cancer or other solid tumors and matched MHC-A11 typing, with written consent for this study; For cancer without expression of KK-LC-1, fresh tumor tissue should be obtained for RNA/DNA sequencing to computationally identify neoantigen peptides that can be captured by specifically personizedly synthesized poly-MHCI which can be further used to fish appropriate T cells from the patient. 2. Perform biopsy to obtain tissue from tumor/lymph node for organoids, TILs, DC and T cells culture, coculture to screening anti-tumor T cells, establish and select monoclonal T cells for TCR cloning; 3. Clone TCR sequence that targets KK-LC-1 or neoantigens; collect PBMCs from the blood of the patients, isolate and activate the T cells and generate the TCR-T cells; 4. Test the quality and killing activity of the TCR-T cells in vitro and then transplant back the patients via systemic (vein and/or artery) or local injections, and follow up closely to collect related clinical data as needed; 5. Evaluate the clinical results as needed.
Interventions
BIOLOGICALTCR-T cells
Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
Sponsors
Tcell Immune (Guangzhou) Science and Technology Ltd.
Second Affiliated Hospital of Guangzhou Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. patients with advanced lung tumor or other solid tumor where biopsy is obtainable 2. Life expectancy \>12 weeks 3. Child-Pugh-Turcotte score \<7 4. Adequate heart,lung,liver,kidney function 5. Available autologous transduced T cells with greater than or equal to 20% expression of targeted TCR sequences determined by flow-cytometry and killing of tumor cells greater than or equal to 20% in cytotoxicity assay 6. Informed consent explained to, understood by and signed by patient/ guardian. Patient/guardian given copy of informed consent. -
Exclusion criteria
1. Had accepted gene therapy before; 2. Tumor size more than 25cm; 3. Severe virus infection such as HBV, HCV, HIV, et al 4. Known HIV positivity 5. History of lung transplantation 6. Active infectious disease related to bacteria, virus,fungi,et al 7. Other severe diseases that the investigators consider not appropriate; 8. Pregnant or lactating women 9. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day) 10. Other conditions that the investigators consider not appropriate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients with Dose Limiting Toxicity | three months | A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the TCR-T cells, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent of Patients with best response as either complete remission or partial remission | three months | Response rates will be estimated as the percent of patients whose best response is either complete remission or partial remission by combining the data from the patients. To compare with historical data, a 95% confidence interval will be calculated for the response rate. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Median TCR-T cell persistence | Five years | Median TCR-T cell persistence will be measured by quantitative rt-PCR. |
Countries
China
Contacts
Primary ContactZhenfeng Zhang, MD,PhD
Backup ContactLiangping Li, MD,PhD
Outcome results
None listed